Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial

On Tuesday, Immix Biopharma Inc. (NASDAQ:IMMX) announced that its cell therapy NXC-201 met its primary endpoint of complete response/CR rate in interim results from the US multi-site NEXICART-2 Phase 1/2 clinical trial. These positive findings for NXC-201, which is a treatment for relapsed/refractory AL Amyloidosis, were presented at an oral presentation at the 2025 ASCO Annual Meeting in Chicago.

Immix Biopharma's NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial

A doctor in a white coat discussing clinical trial results with a patient in an oncology practice.

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the median number of prior therapies for patients in the trial was 4 (ranging from 2-12), and all patients had baseline relapsed/refractory AL Amyloidosis organ involvement. Following NXC-201 treatment, all patients normalized pathological disease markers. The remaining 3 patients are bone marrow minimum residual disease/MRD negative, which Immix believes predicts future CRs.

NXC-201 showed a strong safety profile, with no neurotoxicity observed and only low-grade cytokine release syndrome. Importantly, no relapses have been recorded to date. Downstream clinical improvements, which includes cardiac and renal organ responses, were also recorded after CRs. Immix Biopharma plans to submit a Biologics License Application/BLA to the FDA for approval of NXC-201, which is a sterically-optimized BCMA-targeted chimeric antigen receptor T/CAR-T cell therapy. NXC-201 has already received Regenerative Medicine Advanced Therapy/RMAT designation from the US FDA and Orphan Drug Designation/ODD by both the US FDA and the European Medicines Agency/EMA.

Immix Biopharma Inc. (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company that develops chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the US and Australia.

While we acknowledge the potential of IMMX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMMX and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.